Candida: Epidemiology and risk factors for non-albicans species;Candida: epidemiología y factores de riesgo para especies no albicans

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 31, Issue 6, 2013, Pages 380-384

  Cornistein, Wanda ^a   Mora, Andrea ^a   Orellana, Nora ^a   Capparelli, Federico Javier ^a   Del Castillo, Marcelo ^a  

^a FLENI   (Argentina)

Author keywords

Candida albicans; Candida non albicans; Epidemiology; Neurological centre; Risk factors

Indexed keywords

AMINOPENICILLIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CARBAPENEM DERIVATIVE; GLYCOPEPTIDE; STEROID;

AIRWAY; ANTIBIOTIC THERAPY; ARTICLE; CANDIDA; CANDIDEMIA; CHEMOTHERAPY; COMORBIDITY; EPIDEMIOLOGY; FUNGAL COLONIZATION; FUNGAL DETECTION; FUNGUS ISOLATION; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; MORTALITY; MYCOSIS; NONHUMAN; OBSERVATIONAL STUDY; OROPHARYNX; OVERALL SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SOLID TUMOR; SPECIES DISTRIBUTION; STEROID THERAPY; URINE;

ADULT; AGED; CANDIDA; CANDIDIASIS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84879409190     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2012.09.011     Document Type: Article

References (23)

1. S.K. Fridkin The changing face of fungal infections in health care settings Clin Infect Dis 41 2005 1455 1460
2. L. Rodero, G. Davel, M. Soria, W. Vivot, S. Cordoba, and C.E. Canteros Estudio multicéntrico de fungemias por levaduras en la República Argentina Rev Argent Microbiol 37 2005 189 195
3. O. Leroy, J.P. Gangneux, P. Montravers, J.P. Mira, F. Gouin, J.P. Sollet AmarCand Study Group Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006) Crit Care Med 37 2009 1612 1618
4. H.M. Blumberg, W.R. Jarvis, J.M. Soucie, J.E. Edwards, J.E. Patterson, M.A. Pfaller National Epidemiology of Mycoses Survey (NEMIS) Study Group Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey Clin Infect Dis 33 2001 177 186
5. M.A. Pfaller, D.J. Diekema, L. Boyken, S.A. Messer, S. Tendolkar, and R.J. Hollis Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis Antimicrob Agents Chemother 49 2005 4795 4797
6. R. Ben-Ami, K. Olshtain-Pops, M. Krieger, I. Oren, J. Bishara, M. Dan Israeli Candidemia Study Group Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection Antimicrob Agents Chemother 56 2012 2518 2523
7. J. Garnacho-Montero, A. Díaz-Martín, and A. Cfayuela-Dominguez Management of invasive Candida infections in non-neutropenic critically ill patients: from prophylaxis to early therapy Int J Antimicrob Agents 32 Suppl 2 2008 S137 S141
8. O. Gudlaugsson, S. Gillespie, K. Lee, J. Vande Berg, J. Hu, and S. Messer Attributable mortality of nosocomial candidemia, revisited Clin Infect Dis 37 2003 1172 1177
9. M.T. Mujica, J.L. Finquelevich, V. Jewtuchowicz, and C.A. Iovannitti Prevalencia de Candida albicans y Candida no albicans en diferentes muestras clínicas. Período 1999-2001 Rev Argent Microbiol 36 2004 107 112
10. G.S. Martin, D.M. Mannino, S. Eaton, and M. Moss The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 2003 1546 1554
11. G. St-Germain, M. Laverdière, R. Pelletier, P. René, A.M. Bourgault, and C. Lemieux Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005 Can J Infect Dis Med Microbiol 19 2008 55 62
12. D.L. Horn, D. Neofytos, E.J. Anaissie, J.A. Fishman, W.J. Steinbach, and A.J. Olyaei Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry Clin Infect Dis 48 2009 1695 1703
13. Consenso Argentino Intersociedades para el manejo de la infección del tracto urinario parte III Rev Panam Infectol 10 2008 48 57
14. A.F. Shorr, D.R. Lazarus, J.H. Sherner, W.L. Jackson, M. Morrel, and V.J. Fraser Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia Crit Care Med 35 2007 1077 1083
15. M. Nucci, F. Queiroz Telles, A. Tobón, A. Restrepo, and A. Colombo Epidemiology of opportunistic fungal infections in Latin America Clin Infect Dis 51 2012 561 570
16. D.H. Kett, and F.G. Cubillos Anidulafungin in the treatment of patients with invasive candidiasis Int J Antimicrob Agents 32 Suppl 2 2008 S99 S102
17. J. Vazquez Anifulafungin: a new echinocandin with a novel profile Clin Ther 27 2005 657
18. M.A. Pfaller, L. Boyken, R.J. Hollis, J. Kroeger, S.A. Messer, and S. Tendolkar In vitro susceptibility of invasive isolates of Candida spp. To anidulafungin, caspofungin, and micafungin: six years of global surveillance J Clin Microbiol 46 2008 150 156 Erratum in: J Clin Microbiol. 2008;46:3184-3185
19. W. Meersseman, K. Lagrou, I. Spriet, J. Maertens, E. Verbeken, and W.E. Peetermans Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study Intensive Care Med 35 2009 1526 1531
20. J. Barenfanger, P. Arakere, R.D. Cruz, A. Imran, C. Drake, and J. Lawhorn Improved outcomes associated with limiting identification of Candida spp. in respiratory secretions J Clin Microbiol 41 2003 5645 5649
21. J.K. Chow, Y. Golan, R. Ruthazer, A.W. Karchmer, Y. Carmeli, and D. Lichtenberg Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit Clin Infect Dis 46 2008 1206 1213
22. D. Rodríguez, B. Almirante, M. Cuenca-Estrella, J.L. Rodríguez-Tudela, J. Mensa, J. Ayats Barcelona Candidemia Project Study Group Predictors of candidaemia caused by non-albicans Candida species: results of a population-based surveillance in Barcelona, Spain Clin Microbiol Infect 16 2010 1676 1682
23. J. Pemán, E. Cantón, J.J. Miñana, J.A. Florez, J. Echeverria, D.N. Ortega Grupo de Estudio FUNGEMYCA Variación de la epidemiología de las fungemias y de la sensibilidad al fluconazol de los aislamientos de hemocultivos en los últimos 10 años en España: resultados del estudio FUNGEMYCA Rev Iberoam Micol 28 2011 91 99